Xilio gets FDA clearance for XTX501 IND, reports Q2 2026 results
The bispecific PD-1/masked IL-2 candidate is set to begin Phase 1 dosing in the second half of 2026 as Xilio's cash runway extends into early 2028.
SEC filing
Latest
1 story
Sign inSign in1 story
The bispecific PD-1/masked IL-2 candidate is set to begin Phase 1 dosing in the second half of 2026 as Xilio's cash runway extends into early 2028.
SEC filing